Local delivery of stabilized chondroitinase ABC degrades chondroitin sulfate proteoglycans in stroke-injured rat brains.
Animals
Axons
/ metabolism
Brain
/ drug effects
Chondroitin ABC Lyase
/ chemistry
Chondroitin Sulfate Proteoglycans
/ drug effects
Drug Liberation
Male
Mutagenesis
/ drug effects
Mutant Proteins
/ genetics
Nanocapsules
/ chemistry
Nerve Regeneration
/ drug effects
Neuroglia
/ metabolism
Polyethylene Glycols
/ chemistry
Proteus vulgaris
/ enzymology
Rats
Rats, Sprague-Dawley
Recombinant Fusion Proteins
/ genetics
Stroke
/ metabolism
src Homology Domains
Affinity release
Chondroitinase ABC
Glial scar
PEGylation
Protein delivery
Protein stability
Rosetta
Site-directed mutagenesis
Stroke
Journal
Journal of controlled release : official journal of the Controlled Release Society
ISSN: 1873-4995
Titre abrégé: J Control Release
Pays: Netherlands
ID NLM: 8607908
Informations de publication
Date de publication:
10 03 2019
10 03 2019
Historique:
received:
13
12
2018
revised:
21
01
2019
accepted:
24
01
2019
pubmed:
29
1
2019
medline:
6
6
2020
entrez:
29
1
2019
Statut:
ppublish
Résumé
Central nervous system (CNS) injuries, such as stroke and spinal cord injuries, result in the formation of a proteoglycan-rich glial scar, which acts as a barrier to axonal regrowth and limits the regenerative capacity of the CNS. Chondroitinase ABC (ChABC) is a potent bacterial enzyme that degrades the chondroitin sulfate proteoglycan (CSPG) component of the glial scar and promotes tissue recovery; however, its use is significantly limited by its inherent instability at physiological temperatures. Here, we demonstrate that ChABC can be stabilized using site-directed mutagenesis and covalent modification with poly(ethylene glycol) chains (i.e. PEGylation). Rosetta protein structure modeling was used to screen >20,000 single point mutations, and four potentially stabilizing mutations were tested in vitro. One of the mutations, N1000G (asparagine ➔ glycine at residue 1000), significantly improved the long-term activity of the protein, doubling its functional half-life. PEGylation of this ChABC mutant inhibited unfolding and aggregation and resulted in prolonged bioactivity with a 10-fold increase in activity compared to the unmodified protein after two days. Local, affinity-controlled release of the modified protein (PEG-N1000G-ChABC) was achieved by expressing it as a fusion protein with Src homology 3 (SH3) and delivering the protein from a methylcellulose hydrogel modified with SH3 binding peptides. This affinity-based release strategy provided sustained PEG-N1000G-ChABC-SH3 release over several days in vitro. Direct implantation of the hydrogel delivery vehicle containing stabilized PEG-N1000G-ChABC-SH3 onto the rat brain cortex in a sub-acute model of stroke resulted in significantly reduced CSPG levels in the penumbra of 49% at 14 and 40% at 28 days post-injury compared to animals treated with the vehicle alone.
Identifiants
pubmed: 30690102
pii: S0168-3659(19)30060-4
doi: 10.1016/j.jconrel.2019.01.033
pii:
doi:
Substances chimiques
Chondroitin Sulfate Proteoglycans
0
Mutant Proteins
0
Nanocapsules
0
Recombinant Fusion Proteins
0
Polyethylene Glycols
3WJQ0SDW1A
Chondroitin ABC Lyase
EC 4.2.2.20
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
14-25Subventions
Organisme : CIHR
Pays : Canada
Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.